Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.
Tamoxifen was granted FDA approval on 30 December 1977.
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia
- Conditions
- Neoadjuvant Endocrine TherapyBreast Cancer
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 300
- Registration Number
- NCT05800197
- Locations
- 🇷🇺
Blokhin's Russian Cancer Research Center, Moscow, Russian Federation
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4300
- Registration Number
- NCT05774951
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%
- Conditions
- Breast CancerBreast Cancer, Early-Onset
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 92
- Registration Number
- NCT05659563
- Locations
- 🇫🇷
Hôpital Tenon AP-HP, Paris, France
🇫🇷Hopital Europeen Georges Pompidou, Paris, France
🇪🇸Institut Català d' Oncologia Badalona, Badalona, Barcelona, Spain
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Tolmar Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05645536
- Locations
- 🇺🇸
Texas Oncology - Central South, Austin, Texas, United States
🇧🇷Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇺🇸Marin Cancer Care, Inc., Greenbrae, California, United States
Tamoxifen Prediction Study in Patients With ER+ Breast Cancer
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT05525481
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8000
- Registration Number
- NCT05514054
- Locations
- 🇮🇹
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia, Candiolo, Torino, Italy
🇮🇹Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy
🇮🇹Aou Ospedali Riuniti Umberto I, Ancona, Italy
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
- Conditions
- HER2-negative Breast CancerStage IIB Breast CancerStage III Breast CancerER-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 220
- Registration Number
- NCT05512364
- Locations
- 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪Pole Hospitalier Jolimont - Hopital Jolimont, Haine-Saint-Paul, Belgium
🇧🇪CHU Site Sainte-Elisabeth-UCL Namur, Namur, Belgium
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Nalagenetics Pte Ltd
- Target Recruit Count
- 150
- Registration Number
- NCT05501158
- Locations
- 🇮🇩
MRCCC Siloam Hospitals Semanggi, Jakarta, DKI Jakarta, Indonesia
ETHAN - ET for Male BC
- Conditions
- Hormone Receptor Negative Breast CarcinomaHormone Receptor-positive Breast CancerMale Breast Cancer
- Interventions
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Jose Pablo Leone
- Target Recruit Count
- 60
- Registration Number
- NCT05501704
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Daré Bioscience, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT05378269
- Locations
- 🇦🇺
Keogh Institute for Medical Research, Nedlands, Western Australia, Australia
🇦🇺PARC Clinical Research, Adelaide, Southern Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.